JD
Therapeutic Areas
Johnson & Johnson Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Talquetamab | Multiple Myeloma | Phase 3 |
| Nipocalimab | Generalized Myasthenia Gravis | Phase 3 |
| JNJ-2113 | Plaque Psoriasis | Phase 3 |
| JNJ-4804 | C. diff Prevention | Phase 3 |
| JNJ-77242113 | Psoriasis | Phase 3 |
| JNJ-3989 | Chronic Hepatitis B | Phase 2 |
| CARVYKTI® (ciltacabtagene autoleucel) | Multiple Myeloma | Phase 3 |
| Erdafitinib | Urothelial Carcinoma | Phase 3 |
Leadership Team at Johnson & Johnson
JR
John Reed, M.D., Ph.D.
EVP, Innovative Medicine R&D
TS
Timothy Schmid
EVP, MedTech Worldwide Chairman
JJ
Joseph J. Wolk
EVP and Chief Financial Officer
VB
Vanessa Broadhurst
EVP, Global Corporate Affairs
PF
Peter Fasolo, Ph.D.
EVP, Chief Human Resources Officer